ARTICLE | Strategy
Actelion, take two
Why fiercely independent Swiss bellwether Actelion agreed to sell to J&J
February 4, 2017 3:07 AM UTC
After surviving takeover attempts, an investor mutiny and a make-or-break gamble on Opsumit macitentan, Actelion Ltd. co-founder and CEO Jean-Paul Clozel finally took a deal management couldn’t refuse.
Johnson & Johnson’s proposed $30 billion acquisition provides shareholders with a handsome return while giving Clozel and his team the opportunity to continue doing R&D...